Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy

Fig. 2

DNMT3A mediates hypermethylation of ELP5. a RT-qPCR analysis of ELP5 transcription levels upon DNMT1, DNMT3a, and DNMT3B stably knockdown in NOZ and GBC-SD cells. b MS-qPCR analysis of ELP5 promoter methylation levels upon DNMT1, DNMT3A, and DNMT3B stably knockdown in NOZ and GBC-SD cells. c ChIP-qPCR analysis of 5mC contents in ELP5 promoter with or without DNMT3A stably silenced in NOZ cells. d Luciferase assay to screen the ELP5 promoter region with the highest pro-transcription activity by transfected with a group of promoter constructs with different 5′ deletions of ELP5 promoter in HEK293T cells. RLU, relative light units. e Luciferase assay of ELP5 promoter (− 450 bp to + 107 bp) activities by ELP5 promoter construct co-transfected with empty vector (EV), wild type (WT), or loss-of-function mutation (R882H) of DNMT3A constructs in HEK293T cells. f-h ChIP-qPCR analysis of 5mC contents in ELP5 promoter (f), RT-qPCR analysis of ELP5 transcription levels (g), and western blot analysis for ELP5 protein levels (h) in both NOZ and GBC-SD cells transfected with EV, WT, or R882H of DNMT3A constructs. Student’s t test for statistical analysis, *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page